Chiantera Vito, Laganà Antonio Simone, Basciani Sabrina, Nordio Maurizio, Bizzarri Mariano
Unit of Gynecologic Oncology, ARNAS "Civico-Di Cristina-Benfratelli", Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, 90127 Palermo, Italy.
Department of Experimental Medicine, Section of Medical Pathophysiology, Food Science and Endocrinology, Sapienza University of Rome, 00161 Rome, Italy.
Life (Basel). 2023 May 24;13(6):1247. doi: 10.3390/life13061247.
is a mucin-degrading bacterium of the intestinal niche, exerting beneficial effects on the host metabolic profile. Accumulating evidence indicated as a promising therapeutic probiotic against metabolic disorders such as obesity, type 2 diabetes and cardiovascular diseases. However, in specific intestinal microenvironments, its excessive enrichment may be not beneficial. Conditions like inflammatory bowel disease (IBD), infection or post-antibiotic reconstitution may not benefit from supplementation. Furthermore, using in patients with endocrine and gynecological disorders-such as polycystic ovary syndrome (PCOS) or endometriosis-that have a higher risk of developing IBD, should be critically evaluated. In addition, a cautionary note comes from the neurological field, as the gut microbiota of patients suffering from Parkinson's disease or multiple sclerosis exhibits a characteristic signature of abundance. Overall, considering these controversial points, the use of should be evaluated on an individual basis, avoiding risking unexpected effects.
是一种肠道生态位中的粘蛋白降解细菌，对宿主代谢谱具有有益作用。越来越多的证据表明，它是一种有前景的治疗性益生菌，可对抗肥胖、2型糖尿病和心血管疾病等代谢紊乱。然而，在特定的肠道微环境中，其过度富集可能并无益处。炎症性肠病（IBD）、感染或抗生素后重建等情况可能无法从其补充中获益。此外，对于患有内分泌和妇科疾病（如多囊卵巢综合征（PCOS）或子宫内膜异位症）且患IBD风险较高的患者使用该菌，应进行严格评估。此外，神经学领域也有警示，因为患有帕金森病或多发性硬化症的患者的肠道微生物群表现出该菌丰度的特征性特征。总体而言，考虑到这些有争议的点，应根据个体情况评估该菌的使用，避免出现意外效果的风险。
